Clinical trial
Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients
NCT00424606
Study timeline
Study start (unknown)2001-06-01Date precision: month
Registry last updated2015-05-20
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
DocetaxelDRUG · verified · RxNorm: docetaxel
EpirubicinDRUG · verified · RxNorm: epirubicin
EpirubicinDRUG · verified · RxNorm: epirubicin
DocetaxelDRUG · verified · RxNorm: docetaxel
Sponsors & collaborators
Hellenic Oncology Research Grouplead sponsor
University Hospital of Cretecollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00424606 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.